Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

Abstract

Liver cancer has become the second and sixth most common cause of cancer-associated deaths in men and women. 1 Hepatocellular carcinoma (HCC) accounts for 75%-85% of patients with liver cancer and is a major health burden worldwide. 2,3 Intrahepatic cholangiocarcinoma (ICC) is a malignant neoplasm occurring in the epithelium of the biliary tract and the second most common primary liver cancer following HCC, accounting for approximately 15% of primary liver cancers and 3% of gastrointestinal tumors. 4,5 As ICC is often asymptomatic in its early stages and detected in advanced stages, curative therapy cannot be identified in many patients with ICC. Chemotherapy is the primary treatment for patients with advanced stage with the combination of gemcitabine and cisplatin (GC therapy); the combination of gemcitabine and S-1; and the triple combination of gemcitabine,